Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2008 | 1 |
2021 | 1 |
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
J Cyst Fibros. 2022 Jul;21(4):675-683. doi: 10.1016/j.jcf.2022.02.003. Epub 2022 Feb 18.
J Cyst Fibros. 2022.
PMID: 35190292
Free article.
Clinical Trial.
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA.
Rayment JH, et al. Among authors: paz diaz h.
Am J Respir Crit Care Med. 2022 Nov 15;206(10):1239-1247. doi: 10.1164/rccm.202204-0734OC.
Am J Respir Crit Care Med. 2022.
PMID: 35771568
Free PMC article.
Clinical Trial.
Item in Clipboard
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
Flume PA, Harris RS, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, Berhane I, Shih JL, Sawicki G.
Flume PA, et al. Among authors: paz diaz h.
J Cyst Fibros. 2023 May;22(3):464-470. doi: 10.1016/j.jcf.2022.12.006. Epub 2022 Dec 27.
J Cyst Fibros. 2023.
PMID: 36581484
Clinical Trial.
Item in Clipboard
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group.
Flume PA, et al. Among authors: paz diaz h.
Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10.
Lancet Respir Med. 2021.
PMID: 33581080
Item in Clipboard
Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD.
Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, Pinto-Plata VM.
Vassaux C, et al. Among authors: paz diaz h.
Eur Respir J. 2008 Nov;32(5):1275-82. doi: 10.1183/09031936.00151707. Epub 2008 Jun 11.
Eur Respir J. 2008.
PMID: 18550609
Free article.
Item in Clipboard
Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD.
Paz-Díaz H, Montes de Oca M, López JM, Celli BR.
Paz-Díaz H, et al.
Am J Phys Med Rehabil. 2007 Jan;86(1):30-6. doi: 10.1097/phm.0b013e31802b8eca.
Am J Phys Med Rehabil. 2007.
PMID: 17304686
Clinical Trial.
Item in Clipboard
Cite
Cite